ASX CODE: CYP

Cynata Therapeutics ASX CYP granted Notice of Allowance from European Patent Office

Cynata Therapeutics receives notice of allowance ahead of patent for stem cell platform

A patent covering a stem cell technology platform developed by Cynata Therapeutics (ASX: CYP) appears on the horizon, following the receipt of a Notice...
Cynata Therapeutics ASX CYP Cymerus patent stem cell technology

Cynata Therapeutics finalises Cymerus patent to treat adverse reactions to cancer immunotherapy

Cynata Therapeutics (ASX: CYP) has wrapped up an IP Australia patent application for therapeutic use of its Cymerus stem cell technology in treating adverse reactions...
Cynata Therapeutics ASX CYP Orphan Drug Designation FDA graft versus host disease bone marrow

Cynata receives key FDA approval to progress GvHD drug candidate

For the second time in as many days, the US Food and Drug Administration (FDA) has granted important permission to an ASX-listed company in...
Cynata Therapeutics ASX CYP trial stem cells treating graft versus host disease

Cynata unveils promising results in treating graft versus host disease with stem cells

Cynata Therapeutics (ASX: CYP) has unveiled “excellent” data from its “world first” clinical trial using its stem cell product CYP-001 in treating steroid resistant...
Cynata Therapeutics ASX CYP Celularity Cymerus

Cynata finds synergy with US-based biotech developer

Australian stem cell and regenerative medicine company Cynata Therapeutics (ASX: CYP) has signed a Memorandum of Understanding (MoU) with Celularity Inc., a US-based biotech...
Cynata Therapeutics ASX CYP clinical trial mesenchymal stem cells

Cynata Therapeutics advance to second cohort in stem cell trial

Stem cell and regenerative medicine company Cynata Therapeutics (ASX: CYP) has received an encouraging early response from the clinical trials of its stem cell...
Cynata Therapeutics CYP ASX clinical trial stem cell graft versus host disease

Cynata Therapeutics enrols first cohort for world first clinical trial

Stem cell and regenerative medicine company Cynata Therapeutics (ASX: CYP) has enrolled its first cohort for its “world first” clinical trial of its stem...

HOT TOPICS

TRENDING POSTS